blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1501850

EP1501850 - NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.05.2008
Database last updated on 14.09.2024
Most recent event   Tooltip09.05.2008Application deemed to be withdrawnpublished on 11.06.2008  [2008/24]
Applicant(s)For all designated states
GENELABS TECHNOLOGIES, INC.
505 Penobscot Drive
Redwood City, CA 94063 / US
[2005/05]
Inventor(s)01 / ROBERTS, Christopher, Don
1060 Continentals Way
Belmont, CA 94002 / US
02 / DYATKINA, Natalia, B.
150 Pacchetti Way
Mountain View, CA 94040 / US
03 / KEICHER, Jesse, D.
818 Fremont Street, Apt. 4
Menlo Park, CA 94025 / US
04 / LIEHR, Sebastian, Johannes, Reinhard
1721 Woodland Ave., 7
East Palo Alto, CA 94303 / US
05 / HANSON, Eric Jason
154 Portola Drive, Apt. 2
San Francisco, CA 94131 / US
 [2005/05]
Representative(s)Sexton, Jane Helen
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[N/P]
Former [2005/05]Sexton, Jane Helen
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date03747674.406.05.2003
[2005/05]
WO2003US14237
Priority number, dateUS20020378624P06.05.2002         Original published format: US 378624 P
US20020392871P28.06.2002         Original published format: US 392871 P
[2005/05]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03093290
Date:13.11.2003
Language:EN
[2003/46]
Type: A2 Application without search report 
No.:EP1501850
Date:02.02.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 13.11.2003 takes the place of the publication of the European patent application.
[2005/05]
Search report(s)International search report - published on:EP18.03.2004
ClassificationIPC:C07H19/02
[2005/05]
CPC:
C07H19/06 (EP,KR,US); C07H19/02 (KR); A61K31/7072 (KR);
A61P31/12 (EP); A61P31/20 (EP); C07H19/052 (EP,US);
C07H19/16 (EP,KR,US); C07H19/22 (EP,US); C07H19/23 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/05]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:NUKLEOSIDDERIVATE ZUR BEHANDLUNG VON HEPATITIS-C-VIRUSINFEKTIONEN[2005/05]
English:NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION[2005/05]
French:DERIVES NUCLEOSIDIQUES DESTINES AU TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HEPATITE C[2005/05]
Entry into regional phase17.11.2004National basic fee paid 
17.11.2004Designation fee(s) paid 
17.11.2004Examination fee paid 
Examination procedure05.12.2003Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.11.2004Amendment by applicant (claims and/or description)
17.11.2004Examination requested  [2005/05]
17.05.2006Despatch of a communication from the examining division (Time limit: M06)
27.11.2006Reply to a communication from the examining division
04.12.2007Application deemed to be withdrawn, date of legal effect  [2008/24]
17.01.2008Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2008/24]
Fees paidRenewal fee
13.05.2005Renewal fee patent year 03
27.03.2006Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.05.200705   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]FR1521076  (MERCK & CO INC) [X] 1,4,7 * examples 8-18 *;
 [X]GB1209654  (MERCK & CO INC [US]) [X] 1,4 * examples 1-13 *;
 [X]WO9413789  (RIBONETICS GMBH [DE], et al) [X] 1,4 * Fig. 5/5 compound 7 *;
 [X]WO0190121  (NOVIRIO PHARMACEUTICALS LTD [KY], et al) [X] 1-10 * page 115 - page 144 *;
 [X]WO0192282  (NOVIRIO PHARMACEUTICALS LTD [IT], et al) [X] 1-10 * pages 111-137 *;
 [PX]WO02057425  (MERCK & CO INC [US], et al) [PX] 1-10 * Examples 61, 62, 116, 118, 119, 122-124, 127-133, 135-139, 144, 146-148, 151-154 *;
 [PX]  - MOORE ET AL, BIOCHEMISTRY, (2002), vol. 41, no. 47, pages 14066 - 14075, XP002250481 [PX] 1,4 * page 14068 *

DOI:   http://dx.doi.org/10.1021/bi026468r
 [PX]  - DIALPAZ ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, (2002), vol. 448, no. 2-3, pages 123 - 131, XP002250482 [PX] 1,4 * P. 124 compounds MeCPA and MeCCPA *

DOI:   http://dx.doi.org/10.1016/S0014-2999(02)01982-9
 [X]  - FRANCHETTI P ET AL, "2'-C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1998), vol. 41, ISSN 0022-2623, pages 1708 - 1715, XP002189348 [X] 1,4,7 * Scheme 1 p. 1709 *

DOI:   http://dx.doi.org/10.1021/jm9707737
 [X]  - HARRY-O'KURU ROGERS E ET AL, "2'C-alkylribonucleosides: design, synthesis, and conformation", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, (1997), vol. 16, no. 7 - 9, ISSN 0732-8311, pages 1457 - 1460, XP002189347 [X] 1,4-10 * P. 1459 compounds 8, 11, 12 *
 [X]  - WOLFE ET AL., J. ORG CHEM, (1997), vol. 62, no. 6, pages 1754 - 1759, XP002250483 [X] 1,4-10 * P. 1755 compounds 17, 18, 19 *

DOI:   http://dx.doi.org/10.1021/jo961893+
 [X]  - WOLFE ET AL., TETRAHEDRON LETTERS, (1995), vol. 36, no. 42, pages 7611 - 7614, XP002250484 [X] 1,4-10 * P.7612 compounds 5a-5b *

DOI:   http://dx.doi.org/10.1016/0040-4039(95)01635-U
 [X]  - GARRETT ET AL., J. AM. CHEM. SOC., (1972), vol. 94, no. 24, pages 8532 - 8541, XP002250485 [X] 1,4 * p. 8533 fifth compound of table I *

DOI:   http://dx.doi.org/10.1021/ja00779a040
 [X]  - BEIGELMAN ET AL., CARBOHYDRATE RESEARCH, (1987), vol. 166, no. 2, pages 219 - 2132, XP009014837 [X] 1,4 * P. 231 compounds 20-22 *

DOI:   http://dx.doi.org/10.1016/0008-6215(87)80059-9
 [X]  - MONNERET ET AL., SYNTHESIS, (1992), no. 8, pages 773 - 778, XP001154225 [X] 1,4 * P. 774 compounds 20 and 23 *

DOI:   http://dx.doi.org/10.1055/s-1992-26224
 [X]  - DUNKEL ET AL., NUCLEOSIDES & NUCLEOTIDES, (1995), vol. 14, no. 3-5, pages 799 - 801, XP009014832 [X] 1,4 * P. 800 compounds 4, 5; P.801 compounds 8, 9 *
 [X]  - ROSENTHAL ET AL., TETRAHEDRON LETTERS, (1970), no. 48, pages 4233 - 4235, XP009014838 [X] 1,4 * page 4233, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S0040-4039(01)98711-8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.